The ultimate goal of the proposal presented herein is to use E. coli as whole cell biocatalysts for the production of a wide variety of TDP-deoxysugars including di- and tri-deoxysugars, amino sugars and branched-chain sugars. These specialized activated hexoses are found as important structural components throughout plant and microbial secondary metabolites often playing a crucial role in conferring activity in bioactive natural products such as antibiotics and anticancer therapeutics. In Phase I, we proposed to investigate a novel approach to produce rare TDP-deoxysugars in Escherichia coli through metabolic engineering. During the Phase I study we successfully modified E. coli AB707 to accumulate TDP-4-keto-6-deoxy-D-glucose (TKDG;a key intermediate of TDP-deoxysugars) through inactivations and overexpression of specific pathway enzymes. Using exogenous TDP-deoxysugar biosynthetic enzymes, the accumulated TKDG pools were converted to specific TDP-deoxysugars in yields up to 80 mg/L, exceeding our Phase I goal. The success of the feasibility study will be expanded in Phase II. Specifically, we will further increase TDP- deoxysugar yields through additional genetic engineering experiments to limit loss of glucose- -phosphate to competing pathways, increase thymidine triphosphates (TTP) pools, reduce catabolite repression by glucose, and optimize fermentation conditions. We will also expand our range of TDP-deoxysugar products by cloning and expressing several exogenous sugar biosynthetic genes for the production of 0 additional complex TDP-deoxysugars. In Phase III we will commercialize the technology by carrying out Partnered R&D programs with strategic partners to make new glycoconjugates, by offering TDP-deoxysugars as well as deoxysugars as research reagents, and by licensing the technology on an application-specific basis.

Public Health Relevance

This project is aimed toward developing E. coli as a whole-cell biocatalyst for the production of activated TDP-deoxysugars. These deoxysugars can be used to make derivatives of natural products with new therapeutic properties, for example, antibiotics that are effective against antibiotic-resistant bacteria.

Agency
National Institute of Health (NIH)
Type
Small Business Innovation Research Grants (SBIR) - Phase II (R44)
Project #
2R44GM100638-02A1
Application #
8715444
Study Section
Special Emphasis Panel (ZRG1)
Program Officer
Marino, Pamela
Project Start
Project End
Budget Start
Budget End
Support Year
2
Fiscal Year
2014
Total Cost
Indirect Cost
Name
Zuchem, Inc.
Department
Type
DUNS #
City
Chicago
State
IL
Country
United States
Zip Code
60612